about
Homodimerization Controls the Fibroblast Growth Factor 9 Subfamily's Receptor Binding and Heparan Sulfate-Dependent Diffusion in the Extracellular MatrixA crystallographic snapshot of tyrosine trans-phosphorylation in actionInhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation.FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological featuresCommon variation in the fibroblast growth factor receptor 2 gene is not associated with endometriosis risk.High frequency of BRAF mutations in nevi.Loss-of-function fibroblast growth factor receptor-2 mutations in melanomaA phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk.Cellular settings mediating Src Substrate switching between focal adhesion kinase tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) tyrosine 734The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression AnalysisSensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN statusA Common Variant at the 14q32 Endometrial Cancer Risk Locus Activates AKT1 through YY1 BindingThe N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.Active Notch1 confers a transformed phenotype to primary human melanocytes.FGFR2 as a molecular target in endometrial cancer.The "melanoma-enriched" microRNA miR-4731-5p acts as a tumour suppressor.Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition.Targeting mutant fibroblast growth factor receptors in cancer.Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers.hSSB1 phosphorylation is dynamically regulated by DNA-PK and PPP-family protein phosphatases.FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.Lineage-specific biomarkers predict response to FGFR inhibition.XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts.p53 prevents progression of nevi to melanoma predominantly through cell cycle regulationOsteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN.Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.Microarray expression profiling in melanoma reveals a BRAF mutation signature.CDKN2A is not the principal target of deletions on the short arm of chromosome 9 in neuroendocrine (Merkel cell) carcinoma of the skin.Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation.Loss of Rearranged L-Myc Fusion (RLF) results in defects in heart development in the mouse.FGFR2 mutations are rare across histologic subtypes of ovarian cancer.Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia.Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.A homologue of the Drosophila Son of sevenless gene maps to mouse chromosome 17.A genome-based strategy uncovers frequent BRAF mutations in melanoma.Lucky draw in the gene raffle.
P50
Q27646372-F20F2C2A-4147-46B7-90D1-E672142E5D06Q27653072-4A21938A-D804-485F-92A5-07750BFE2208Q27851447-871B349A-6374-424B-88C9-0E5E5C00EDA0Q28731816-E74AC9D3-C397-41F5-80AF-AE0109D9A8F8Q33988532-196F8B5C-22A2-4144-9445-56749F5A8D51Q34160519-D6E41903-8B7D-4C53-93B2-3838112BCDC8Q34520671-10A41115-58A5-4F35-8E59-8E2DB358D160Q34781699-6CAFAA37-FB37-40B7-8039-64F192B4635CQ34842280-8BDA2641-A23B-4215-B910-33FBBE546CFFQ35063160-9CA6A510-2BDE-402F-AA8D-1F8AF4BDE264Q35605121-C597867B-D314-4AAC-9574-0AB81D498821Q35947544-8E045323-D2CB-4AEB-B62B-36073E0663FEQ36560775-647DC194-CF14-4361-B7F4-B8F7518F88D0Q37005064-6BB32ED1-2C1B-4D54-B446-F852564845F5Q37061044-CEC59DD2-4159-4C88-8EB9-DC9DCAAE451DQ37371156-DC9D9737-D625-48FA-BC56-24886BE4AA5FQ37401322-B7FC6EE1-E62E-48A2-B363-89E610D4794FQ37580297-002BFE13-A728-42FF-AF14-3B6AFA3D5DA4Q37705031-30677F7D-5FB1-4407-A3F6-B75828316173Q37849013-C142011D-90FC-4810-B3C2-E350F7663720Q38703322-A719FA8F-9D5D-42A6-85B9-5A5F42C712F5Q38719587-120D9120-E436-401A-BFE3-60C275E881ECQ38816856-0625BB71-73D9-432B-88E3-AC9988B41975Q38897134-9191EBFE-E5AD-4762-9975-86235BFFEC33Q39228091-DA975321-1F52-4BCF-8C22-FBEDD50CCC5BQ39261084-59069B74-FBAD-4CCD-8065-0273B2815E5AQ39654655-8E7BAA73-E755-4F2D-A772-984183138517Q40298565-F7E7160E-3D6E-4600-B791-7D2C9F6E5602Q40396792-A8BB06DA-AE3B-47FD-91EA-04103AF300F2Q40572664-3EEBE1E6-9ADD-44C6-A49A-842FF19680F5Q40795427-AAD1F642-7A96-49D6-B0CA-EF9C4BA13E72Q42030378-60E8F76D-2BBF-48E0-AC43-0F459A67FBD9Q42775156-01EC2628-0A31-4C76-AA91-ECD77CDCE1CCQ42813018-4A699C0E-1BB2-4152-9B59-F345F4BA0505Q43415575-22E243C8-827A-4229-ACA5-3B62E05E9BC3Q48250298-D32CC406-2281-4713-800C-040F1F595A20Q49158742-89686831-2F7C-43CA-918C-F6A8F8615DC4Q52544670-5CED2653-0EB2-415E-B675-0B63852F0E5FQ53388101-E106AB61-9214-4D47-AE19-F0CA638F0B63Q53389025-C4545509-965A-490F-9CF1-49C0C7FE98A8
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Pamela M. Pollock
@ast
Pamela M. Pollock
@en
Pamela M. Pollock
@es
Pamela M. Pollock
@sl
type
label
Pamela M. Pollock
@ast
Pamela M. Pollock
@en
Pamela M. Pollock
@es
Pamela M. Pollock
@sl
prefLabel
Pamela M. Pollock
@ast
Pamela M. Pollock
@en
Pamela M. Pollock
@es
Pamela M. Pollock
@sl
P106
P1153
7006251946
P21
P31
P496
0000-0001-8420-1026